RAS inhibitors in hematologic cancers: Biologic considerations and clinical applications

Investigational New Drugs

Volumn 17, Issue 2, 1999, Pages 137-143

  Beaupre, Darrin M ^a   Kurzrock, Razelle ^b,c  

^a JACKSON MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Department of Bioimmunotherapy Box 302 ^*  (United States)

Author keywords

Hematologic cancers; RAS inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; LIMONENE; PERILLYL ALCOHOL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN;

ADVANCED CANCER; ANOREXIA; ARTICLE; BLOOD DISEASE; CLINICAL TRIAL; FATIGUE; GASTROINTESTINAL TOXICITY; GENE TARGETING; GRANULOCYTOPENIA; HUMAN; NAUSEA; NEPHROTOXICITY; NONHUMAN; ONCOGENE RAS; PATHOGENESIS; PRIORITY JOURNAL; VOMITING;

EID: 0032793889     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006319116226     Document Type: Article

References (81)

1. Mangues R, Pellicer A: Ras activation in experimental carcinogenesis. Semin Cancer Biol 3: 229-239, 1992
2. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49: 465-75, 1987
3. Hirsch-Ginsberg C, Lemaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ, Trujillo JM, Lee MS, Stass SA: Ras mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia but are prevalent in chronic myelomonocytic leukemia. Blood 76: 1214-1219, 1990
4. Nounou R, Estey E, Beran M, Kantarjian H, Frireich EJ, Albitar M. Mutation of K-, N-, and H-RAS oncogenes in patients with myelodysplastic syndrome (MDS). Blood 88 (Suppl 1), pp 208b (abstract #3559), 1996
5. Imamura N, Kuramoto A, Ishihara H, Shimizu S: Detection of high incidence of H-RAS oncogene point mutations in acute myelogenous leukemia. Am J Hematol 43: 151-153, 1993
6. Ahuja HG, Foti A, Bareli M, Cline MJ: The pattern of mutational involvement of ras genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 75: 1684-1690, 1990
7. Janssen JWG, Steenvoorden ACM, Lyons J, Anger B, Bohlke JU, Bos JL, Seliger H, Bartram CR: Ras gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci USA 84: 9228-9232, 1987
8. Kalra R, Paderanga DC, Olson K, Shannon KM: Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 84: 3435-3439, 1994
9. Miyauchi J, Asada M, Sasaki M, Tsunematsu Y, Kojima S, Mizutani S: Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood 83: 2248-2254, 1994
10. Corradini P, Ladetto M, Inghirami G, Boccadoro M, Pileri A: N- and K-ras oncogenes in plasma cell dyscrasias. Leuk Lymphoma 15: 17-20, 1994
11. Paquette RL, Berenson J, Lichtenstein A, McCormick F, Koeffler HP: Oncogenes in multiple myeloma-point mutations of N-ras. Oncogene 5: 1659-1663, 1990
12. Van Ness B, Leong T, Quam L, Liu P, Billadeau D, Kay N, Oken MM, Greipp P, Kyle R: Distinct ras mutations in multiple myeloma (MM) correlate with tumor burden and survival: Analysis of ECOG phase III trial E9486/9487. Blood 86: 442a, 1995
13. Parker J, Mufti GJ: Ras and myelodysplasia: lessons from the last decade. Semin Hematol 33: 206-224, 1996
14. Lubbert M, Mirro J, Miller CW, Kahan J, Isaac G, Kitchingman G, Mertelsmann R, Herrmann F, McCormick F, Koeffler HP: N-Ras gene point mutations in childhood actue lymphocytic leukemia correlate with a poor prognosis. Blood 75: 1163-1169, 1990
15. Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R: Analysis of Ras oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA 85: 9268-9272, 1988
16. McKay IA, Marshall CJ, Cales C, Hall A: Transformation and stimulation of DNA synthesis in NIH-3T3 cells are a titratable function of normal p21N-ras expression. EMBO J 5: 2617-2621, 1986
17. Mangues R, Seidman I, Gordon JW, Pellicer A: Overexpression of the N-ras proto-oncogene, not somatic mutational activation, associated with malignant tumors in transgenic mice. Oncogene 7: 2073-2076, 1992
18. Wilson DM, Yang DJ, Dillberger JE, Dietrich SE, Maher VM, McCormick JJ: Malignant transformation of human fibroblasts by a transfected N-ras oncogene. Cancer Res 50: 5587-5593, 1990
19. Gallagher A, Padua RA, al-Sabah A, Hoy T, Burnett AK, Darley RL: Aberrant expression of p21RAS but not p120GAP is a common feature of myelodysplasia. Leukemia 9: 1833-1840, 1995
20. Shen WP, Aldrich TH, Venta-Perez G, Franza BR, Jr., Furth ME: Expression of normal and mutant ras proteins in human acute leukemia. Oncogene 1: 157-165, 1987
21. Gougopoulou DM, Kiaris H, Ergazaki M, Anagnostopoulos NI, Grigoraki V, Spandidos DA: Mutations and expression of the ras family genes in leukemias. Stem Cells 14: 725-729, 1996
22. Thorn J, Molloy P, Iland H: SSCP detection of N-ras promoter mutations in AML patients. Exp Hematol 23: 1098-1103, 1995
23. Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Wiess R, Tamanoi F: The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GT-Pase and complements ira mutants of S. cerevisiae. Cell 63: 835-841, 1990
24. Passmore SJ, Hann IM, Stiller CA, Ramani P, Swansbury GJ, Gibbons B, Reeves BB, Chessells JM: Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 85: 1742-1750, 1995
25. Shannon KM, Watterson J, Johnson P, P OC, Lange B, Shah N, Steinherz P, Kan YW, Priest JR: Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 79: 1311-1318, 1992
26. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K: Loss of NF1 results in activation of the ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12: 144-148, 1996
27. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG: NF1 deficiency causes ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 12: 137-143, 1996
28. Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, Shannon KM: Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 92: 267-272, 1998
29. Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M, Shannon K: Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 336: 1713-1720, 1997
30. Urbano-Ispizua A, Gill R, Matutes E, Levi S, Wiedemann LM, Catovsky D, Marshall CJ: Low frequency of ras oncogene mutations in Philadelphiapositive acute leukemia and report of a novel mutation H61 leu in a single case. Leukemia 6: 342-346, 1992
31. Kurzrock R, Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319: 990-998, 1988
32. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75: 175-185, 1993
33. Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN, Boswell HS: Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 52: 1838-1847, 1993
34. Cortez D, Stoica G, Pierce JH, Pendergast AM: The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Rasdependent signaling pathway. Oncogene 13: 2589-2594, 1996
35. Cortez D, Reuther G, Pendergast AM: The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15: 2333-2342, 1997
36. Sawyers CL, McLaughlin J, Witte ON: Genetic requirement for ras in the transformation of fibroblasts and hematopoietic cells by the bcr-abl oncogene. J Exp Med 181: 307-313, 1995
37. Sanchez-Garcia I, Martin-Zanca D: Regulation of Eel-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol 267: 225-228, 1997
38. Beaupre DM, Talpaz M, Marini III FC, Cristiano RJ, Roth JA, Estrov Z, Albitar M, Freedman MH, Kurzrock R: Autocrine interleukin-'lg production in leukemia: Ebidence for the involvement of mutated RAS. Cancer Research, in press
39. Estrov Z, Kurzrock R, Talpaz M: Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. Leukemia and Lymphoma 10: 407-418, 1993
40. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M: Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity. Blood 78: 1476-1484, 1991
41. Estrov Z, Kurzrock R, Estey E, Wetzler M. Ferrajoli A. Harris D, Blake M, Gutterman JU, Talpaz M: Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 79: 1938-1945, 1992
42. Beaupre DM, Kurzrock R: RAS and leukemia: From basic mechanisms to gene-directed therapy. J Clinical Oncology 17: 1071-1079, 1999
43. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15: 2755-2765, 1997
44. Bos JL, Verlaan-de Vries M, Marshall CJ, Veeneman GH, van Boom JH, van der Eb AJ: A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. Nucleic Acids Res 14: 1209-1217, 198
45. Pulciani S, Santos E, Long LK, Sorrentino V, Barbacid M: ras gene Amplification and malignant transformation. Mol Cell Biol 5: 2836-2841, 1985
46. Yokota J, Tsunetsugu-Yokota Y, Battifora H, Le Fevre C, Cline MJ: Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science 231: 2S1-2S5, 1986
47. Tamanoi F: Inhibitors of res farnesyltransferases. Trends Biochem Sci 18: 349-353, 1993
48. Cox AD, Der CJ: The ras/cholesterol connection: implications for pas oncogenecity. Grit Rev Oncog 3: 365-400, 1992
49. Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, C.J. D: Farnesol modification of Kirsten-ras axon 4B protein is essential for transformation. Proc Natl Acad Sci USA 87: 3042-3046, 1990
50. James GL, Brown MS, Cobb MH, Goldstein JL: Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in HPas-transformed Rat-i cells, but not in untransformed cells. J Biol Chem 269: 27705-27714, 1994
51. Gana-Weisz M, Haklai R, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y: The Pas antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. Biochem Biophys Res Commun 239: 900-904, 1997
52. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM: Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 272: 14093-14097, 1997
53. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK: K- and N-Ras are .geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272: 14459-14464, 1997
54. Sebti S, Hamilton AD: Inhibitors of prenyl transferases. Curr Coin Oncol 9: 557-561, 1997
55. Gelb MH, Tamanoi F, Yokoyama K, Ghomashchi F, Esson K. Gould MN: The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett 91: 169-175, 1995
56. Gould MN: Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect 105: 977-979, 1997
57. Haag JD, Gould MN: Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34: 477-483, 1994
58. Crowell FL, Ren Z, Lin S, Vedejs E, Gould MN: Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 47: 1405-1415, 1994
59. Hohl RJ, Lewis K: Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 270: 17508-17512, 1995
60. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC, Jr.: Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells [see comments]. Science 260: 1937-1942, 1993
61. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of rasdependent transformation by a farnesyltransferase inhibitor [see comments]. Science 260: 1934-1937, 1993
62. Garcia M, Rowell C, Ackermann K, Kowalczyk JJ, Lewis MD: Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J Biol Chem 268: 18415-18418, 1993
63. Hunt JT, Lee VG, Leftheris K, Seizinger B, Carboni J, Mabus J, Ricca C, Yan N, Manne V: Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. J Med Chem 39: 353-358, 1996
64. Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, Patel DV, Patel MM, Schmidt RJ, Weller HN, Andahazy ML, Carboni JM, Gullo-Brown JL, Lee FY, Ricca C, Rose WC, Yan N, Barbacid M, Hunt JT, Meyers CA, Seizinger BR, Zahler R, Manne V: Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vive activity. J Med Chem 39: 224-236, 1996
65. Manne V, Yan N, Carboni JM, Tuomari AV, Ricca CS, Brown JG, Andahazy ML, Schmidt RJ, Patel D, Zahler R, Weinmann R, Der CJ, Cox AD, Hunt JT, Gordon EM, Barbacid M, Seizinger BR: Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene 10: 1763-1779, 1995
66. Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V: Farnesyltransferase inhibitors block the neurofibromatosis type I(NF1) malignant phenotype. Cancer Res 55: 3569-3575, 1995
67. Elegbede JA, Elson CE, Tanner MA, Qureshi A, Gould MN: Regression of rat primary mammary tumors following dietary d-limonene. J Natl Cancer inst 76: 323-325, 1986
68. Haag JD, Lindstrom MJ, Gould MN: Limonene-induced regression of mammary carcinomas. Cancer Res 52: 4021-4026, 1992
69. Anonymous: Clinical development plan: I-perillyl alcohol. J Cell Biochem Suppl 26: 137-148, 1996
70. Mills JJ, Chari RS, Boyer IJ, Gould MN, Jirtle RL: Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 55: 979-983, 1995
71. Stark MJ, Burke YD, McKinzie JH, Ayoubi AS, Crowell FL: Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol, Cancer Lett 96: 15-21, 1995
72. Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey HH: Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 4: 1159-1184, 1998
73. Zweibel J, Ho P, Sepelak SE, Saunders J, Cheson ED, Nelson A: Clinical trials referral resource. Clinical trials with perillyl alcohol. Oncology 11: 1817, 1820, 1997
74. McNamee D: Limonene trial in cancer. Lancet 342: 801, 1993
75. Kohl NE, Wilson FR, Mosser SD, Giuliani E, DeSolms SJ, Conner MW, Anthony NJ, Holtz WJi Gomez RP, Lee TJ, Smith RL, Graham SL, Hartman GD, Gibbs JB, Oliff A: Protein farnesyltransferase inhibitors block the growth of raspdependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141-9145, 1994
76. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K, et al.: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice [see comments]. Nat Med 1: 792-797, 1995
77. Sun J, Qian Y, Hamilton AD, Sebti SM: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55: 4243-4247, 1995
78. Mangues R, Corral T, Kohl NE, Symmans WF, Lu S, Malumbres M, Gibbs JB, Oliff A, Pellicer A: Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 58: 1253-1259, 1998
79. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant K-ras genes. Cell 53: 549-554, 1988
80. Hruban Rvan Mansfeld AD, Offerhaus GJ, Van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL: K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis allele-specific oligonucleotide hybridization. Am J Pathol 143: 545-554, 1993
81. Wang ZY, Liu TH, Cui OC: Gene diagnosis of pancreatic adenocarcinoma. Chin J Pathol 23: 270-273, 1994